Introduction {#s1}
============

Osteoporosis is a common skeletal disease characterized by increased bone fragility and risk of fracture ([@B38]; [@B15]). As an important cause of morbidity and mortality in people over 65 years, osteoporotic fracture leads to pain and loss of functional ability to these patients, and medical costs for the prevention and treatment of fractures have become substantial for both the developed and the developing countries ([@B29]). Therefore, the identification of factors that may affect the development of osteoporotic fracture is of significance for the prevention and treatment of the disease. Conventionally, many factors have been considered to potentially increase the risk of osteoporotic fracture, including aging, low bone mineral density (BMD), obesity, comorbidities of diabetes and vascular diseases, as well as poor dietary habits with excessive alcohol consumption, and low supplements of calcium and vitamins ([@B12]).

Besides, some medications that influence the calcium homeostasis of the body are also suggested to affect the risk of osteoporotic fracture. Thiazide diuretics, one of the most commonly prescribed categories of medications for patients with hypertension and other cardiovascular diseases ([@B30]), have been suggested to favorably affect BMD *via* their efficacy for lowering the urinary excretion of calcium ([@B36]; [@B1]). Indeed, early observational studies have demonstrated that users of thiazide diuretics are associated with greater BMD as compared with nonusers ([@B25]; [@B36]). Moreover, these findings were further confirmed by results of randomized controlled trials (RCTs) which showed that thiazide diuretics are associated with better preserved BMD as compared with placebo in high-risk people of osteoporosis, such as participants over 65 and postmenopausal women ([@B41]; [@B43]; [@B24]). Therefore, it was hypothesized that the benefits of thiazide diuretics on BMD may translate to the prevention of osteoporotic fractures. Subsequently, many observational studies have been published to evaluate the potential association between use of thiazide diuretics and the risk of osteoporotic fracture ([@B23]; [@B8]; [@B28]; [@B14]; [@B17]; [@B35]; [@B27]; [@B37]; [@B6]; [@B7]; [@B33]; [@B40]; [@B10]; [@B31]; [@B5]; [@B18]; [@B26]). Although the findings of these studies were inconsistent, previous meta-analyses by including these studies generally indicated that use of thiazide diuretics are associated with about 20% reduced risk of fracture events, mainly driven by studies with primary outcomes of hip fractures ([@B22]; [@B45]; [@B2]; [@B46]). However, both case-control and cohort studies were included in these meta-analyses and including of case-control studies may introduce additional bias ([@B3]). Moreover, substantial recently published cohort studies were not included in previous meta-analyses ([@B37]; [@B6]; [@B7]; [@B33]; [@B40]; [@B10]; [@B31]; [@B5]; [@B18]; [@B26]), and an updated meta-analysis is therefore needed to summarize current understanding of the association between thiazide diuretics and risk of osteoporotic fracture. In addition, although the optimal strategy to evaluate the above hypothesis is to perform RCTs, due to the potential moderate effect of thiazide diuretics on fracture risk, these RCTs remain unavailable because too many high-risk osteoporotic participants are needed to make the studies of adequate power to detect the potential efficacy of thiazides ([@B22]). Therefore, in this study, we performed an updated meta-analysis of cohort studies to systematically evaluate the potential association between use of thiazide diuretics and the risk of overall osteoporotic fracture incidence.

Materials and Methods {#s2}
=====================

The meta-analysis was performed in accordance with the MOOSE (meta-analysis of observational studies in epidemiology) ([@B39]) and Cochrane's Handbook ([@B20]) guidelines.

Literature Search {#s2_1}
-----------------

Databases of PubMed and Embase were searched from the index date for relevant records, using the combinations of the following terms (1) "diuretic" OR "diuretics" OR "thiazide" OR "thiazides" OR "hydrochlorothiazide" OR "chlorthalidone", "bendroflumethiazide" OR "chlorothiazide" OR "cyclothiazide" OR "methyclothiazide" OR "hydroflumethiazide" OR "trichlormethiazide" OR "benzthiazide" OR "polythiazide" OR "buthiazide" OR "cyclopenthiazide" OR "metolazone" OR "quinethazone" OR "fenquizone" OR "clorexolone" OR "clopamide" OR "indapamide" OR "diapamide" OR "isoindapamide" OR "mefruside" OR "xipamide"; AND (2) "fracture"; AND (3) "prospective" OR "prospectively" OR "retrospective" OR "retrospectively" OR "followed" OR "follow-up" OR "cohort" OR "cohorts". The search was limited to studies in humans and published in English language. The reference lists of original and review articles were also analyzed using a manual approach. The final literature search was performed on February 26, 2019.

Study Selection {#s2_2}
---------------

Articles were included in the meta-analysis if they met all of the following criteria: (1) published as full-length article in English; (2) reported as cohort studies (prospective or retrospective, regardless of sample size or the follow-up duration); (3) included adult population (≥ 18 years of age) without fracture at baseline; (4) use of thiazide diuretics were defined as exposure of interest at baseline, while participants that did not use thiazide diuretics were defined as controls; (5) documented the incidence of any osteoporotic fracture during follow-up; and (6) reported the risk RRs and their corresponding 95% CIs for the incidence of osteoporotic fracture comparing participants that used thiazide diuretics at baseline to those did not use thiazide diuretics. Reviews, letters, editorials, nonhuman studies, and studies with designs other than cohort study were excluded.

Data Extracting and Quality Evaluation {#s2_3}
--------------------------------------

Literature search, data extraction, and quality assessment of the included studies were performed independently by two reviewers (J.W. and K.S.) according to the predefined inclusion criteria. Discrepancies were resolved by consensus. Data that were extracted include: (1) name of first author, publication year, and country where the study was performed; (2) design characteristics (prospective or retrospective); (3) sources, characteristics, and numbers of the participants; (4) strategies to confirm the using of thiazide diuretics at baseline; (5) enrollment year and follow-up durations; (6) definitions of fracture outcomes, number of cases with osteoporotic fracture, and strategies to confirm facture outcome during follow-up; and (7) variables adjusted when presenting the results. The quality of each study was evaluated using the Newcastle-Ottawa Scale ([@B44]) which ranges from 1 to 9 stars and judges each study regarding three aspects: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest.

Statistical Analyses {#s2_4}
--------------------

We used RRs as the general measure for the association between use of thiazide diuretics at baseline and the incidence of fracture. Data of RRs and their corresponding standard errors (SEs) were calculated from 95% CIs or p values, and were logarithmically transformed to stabilize variance and normalized the distribution ([@B20]). The Cochrane's Q test and I^2^ test were used to evaluate the heterogeneity among the included cohort studies ([@B21]). A significant heterogeneity was considered if I^2^ \> 50%. We used a random-effect model to synthesize the RR data because this model is considered as a more generalized method which incorporates of the potential heterogeneity ([@B20]). Sensitivity analyses, by removing individual study one at a time, were performed to test the robustness of the results ([@B32]). Predefined subgroup analyses were performed to evaluate whether the association between the use of thiazide diuretics at baseline and the incidence of fracture was affected by study design characteristics, sex of the participants, number of the participants, population characteristics, follow-up durations, site of fractures, strategies to confirm use of thiazide diuretics, and the numbers of variables adjusted when presenting the results. Moreover, potential publication bias was assessed by funnel plots with the Egger regression asymmetry test ([@B13]). We used the RevMan (Version 5.1; Cochrane Collaboration, Oxford, UK) and STATA software for the meta-analysis and statistics.

Results {#s3}
=======

Literature Search {#s3_1}
-----------------

The flowchart of database search was presented in [**Figure 1**](#f1){ref-type="fig"}. Briefly, 1,842 articles were found *via* initial literature search of the PubMed and Embase databases, and two studies were found *via* manual search of the reference lists of the review articles. After exclusion of 152 duplications, 1,692 articles underwent screening. Subsequently, 1,629 were excluded through screening of the titles and abstracts mainly because they were not relevant to the purpose of the meta-analysis. Subsequently, 63 potential relevant records underwent full-text review. Of these, 46 were further excluded because 21 of them were case-control studies, 15 were reports of medications other than thiazide diuretics as exposure, four were repeated reports of included cohorts, four were studies evaluating the association between hyponatremia and fracture risk, and the other two did not report the incidence data of fracture outcome. Finally, 17 cohort studies were included ([@B23]; [@B8]; [@B28]; [@B14]; [@B17]; [@B35]; [@B27]; [@B37]; [@B6]; [@B7]; [@B33]; [@B40]; [@B10]; [@B31]; [@B5]; [@B18]; [@B26]).

![Flowchart of database search and study identification.](fphar-10-01364-g001){#f1}

Study Characteristics and Quality Evaluation {#s3_2}
--------------------------------------------

The characteristics of the included studies were summarized in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}. Overall, we included 17 cohort studies ([@B23]; [@B8]; [@B28]; [@B14]; [@B17]; [@B35]; [@B27]; [@B37]; [@B6]; [@B7]; [@B33]; [@B40]; [@B10]; [@B31]; [@B5]; [@B18]; [@B26]) with a total of 3,537,504 participants. Eight of the included studies were performed in North America ([@B23]; [@B8]; [@B14]; [@B37]; [@B6]; [@B7]; [@B31]; [@B18]), six in Europe ([@B17]; [@B35]; [@B27]; [@B33]; [@B40]; [@B5]), and the other three in Australia or Asia ([@B28]; [@B10]; [@B26]). Nine of them were designed as prospective cohort studies ([@B23]; [@B8]; [@B28]; [@B14]; [@B17]; [@B35]; [@B27]; [@B37]; [@B31]), while the other eight were retrospective cohort studies ([@B6]; [@B7]; [@B33]; [@B40]; [@B10]; [@B5]; [@B18]; [@B26]). The sample sizes of the included studies varied between 820 and 1,586,554. Ten studies included community-dwelling general population ([@B23]; [@B8]; [@B28]; [@B14]; [@B17]; [@B35]; [@B27]; [@B33]; [@B40]; [@B31]), five included patients with hypertension ([@B37]; [@B6]; [@B10]; [@B5]; [@B18]), while the other two included patients with new-onset stroke or spinal cord injury ([@B7]; [@B26]). Baseline use of thiazide diuretics was confirmed *via* self-report by the patients in seven studies ([@B23]; [@B8]; [@B28]; [@B14]; [@B17]; [@B27]; [@B31]), while in the other studies, use of thiazide diuretics were confirmed based on the prescription records ([@B35]; [@B37]; [@B6]; [@B7]; [@B33]; [@B40]; [@B10]; [@B5]; [@B18]; [@B26]). With a mean follow-up between 0.5 to 11 years, 312,246 cases of osteoporotic fracture occurred based on the reports from the patients or general practitioners, or identified from healthcare databases. For the definitions of osteoporotic fracture outcomes, hip fracture was reported in nine studies ([@B23]; [@B8]; [@B14]; [@B17]; [@B35]; [@B37]; [@B6]; [@B33]; [@B26]), while some studies reported the overall incidences of osteoporotic fractures ([@B8]; [@B28]; [@B27]; [@B37]; [@B40]; [@B10]; [@B5]; [@B18]). When presenting the results, potential confounding variables such as age, sex, comorbidities, baseline BMD, and concurrent medications et al. were adjusted variably. The qualities of the included cohorts were generally good, with NOS scores ranging between 6 and 9.

###### 

Baseline characteristics of the included studies.

  Study    Country           Design   Participants characteristics                                               Number of participants   Age     Male   Enrollment year   Thiazide ascertainment
  -------- ----------------- -------- -------------------------------------------------------------------------- ------------------------ ------- ------ ----------------- ----------------------------------------------------------
                                                                                                                                          years   \%                       
  [@B23]   USA               PC       Community-based population ≥ 65 years                                      9,518                    74.2    39     1981∼1983         Self-report
  [@B8]    USA               PC       Community-based women ≥ 65 years                                           9,704                    71.8    0      1986∼1988         Self-report
  [@B28]   Australia         PC       Community-based population ≥ 60 years                                      820                      NA      100    1989              Self-report
  [@B14]   USA               PC       Women aged 36 to 61 years                                                  83,728                   49.2    0      1982              Self-report
  [@B17]   Sweden            PC       Community-based population ≥ 75 years                                      1,608                    82      NA     1987              Self-report
  [@B35]   the Netherlands   PC       Community-based population ≥ 55 years                                      7,891                    68.9    38.9   1990∼1993         Prescriptions from computerized pharmacies
  [@B27]   Germany           PC       Community-based population aged 55∼74 years                                1,793                    62.3    46.5   1984∼1985         Self-report
  [@B37]   USA               PC       Hypertensive patients ≥ 65 years with single antihypertensive medication   376,061                  80.2    19.3   NA                Prescription filling by Medicare
  [@B6]    Canada            RC       Hypertensive patients ≥ 65 years                                           301,591                  80.8    19.3   2000              Prescription drugs database
  [@B7]    USA               RC       Hospitalized men with spinal cord injury                                   6,969                    58.2    100    2002              Prescription based on a clinical administrative database
  [@B33]   Norway            RC       Community-based population ≥ 60 years                                      906,422                  72.8    44     2004∼2010         National prescription database
  [@B40]   Denmark           RC       Community-based population ≥ 65 years                                      1,586,554                74.8    47.2   1999∼2012         National prescription database
  [@B31]   USA               PC       Community-based women ≥ 55 years                                           55,780                   66.7    0      2002∼2012         Self-report
  [@B10]   China             RC       Hypertensive patients ≥ 65 years                                           1,144                    75.9    43.6   2002              Prescription database
  [@B26]   China             RC       Hospitalized patients with new-onset ischemic stroke                       7,470                    NA      57.6   2000∼2011         Prescription database
  [@B18]   USA               RC       Hypertensive patients ≥ 65 years                                           122,629                  75      39     2008∼2011         Prescription filling by Medicare
  [@B5]    Sweden            RC       Hypertensive patients ≥ 45 years                                           57,822                   66      45     2001∼2008         Prescribed Drug register

NA, not available; PC, prospective cohort; RC, retrospective cohort.

###### 

Characteristics of follow-up and outcome of the included studies.

  Study    Follow-up   Fracture ascertainment                                    Fracture cases   Fracture sites                          Adjusted factors                                                                                                                                                                                                                                                                                                                                                                                                                NOS scores
  -------- ----------- --------------------------------------------------------- ---------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
           years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  [@B23]   3.6         Self-report or medical record confirmed                   242              Hip                                     Age, sex, impaired mobility, BMI, smoking, alcohol consumption, and history of DM                                                                                                                                                                                                                                                                                                                                               8
  [@B8]    3.3         Self-report or radiography confirmed                      1,113            Osteoporotic fracture (including hip)   Age, weight, functional status, total calcium intake, years of estrogen replacement, self-reported health status, and level of distal radius bone mass                                                                                                                                                                                                                                                                          8
  [@B28]   5           Radiography confirmed                                     166              Osteoporotic fracture                   Age, BMD                                                                                                                                                                                                                                                                                                                                                                                                                        6
  [@B14]   9.2         Self-report                                               1,845            Forearm and hip                         Age, follow-up period, BMI, menopausal status, postmenopausal estrogen use, smoking, alcohol drinking, dietary intake of calcium, vitamin D, histories of heart diseases and osteoporosis                                                                                                                                                                                                                                       8
  [@B17]   4.5         Inpatient register system confirmed                       134              Hip                                     Age, sex, education, institution as residence, limitation of activities of daily living, histories of stroke, tumor, and cognitive impairment                                                                                                                                                                                                                                                                                   8
  [@B35]   7.4         GP-report                                                 281              Hip                                     Age, sex, lower-limb disability, BMI, estrogen use, and current smoking                                                                                                                                                                                                                                                                                                                                                         8
  [@B27]   10.7        Self-report                                               263              Osteoporotic fracture                   None                                                                                                                                                                                                                                                                                                                                                                                                                            6
  [@B37]   0.5         Health care utilization data confirmed                    2,543            Osteoporotic fracture (including hip)   Age, sex, race, other medications, comorbidity scores, BMD and histories of osteoporosis                                                                                                                                                                                                                                                                                                                                        8
  [@B6]    10          Health care database confirmed                            1,463            Hip                                     Age, sex                                                                                                                                                                                                                                                                                                                                                                                                                        7
  [@B7]    5           Health care registry confirmed                            832              Hip                                     Age, race, severity of spinal cord injury, Charlson comorbidity index, history of seizers, and concurrent medications                                                                                                                                                                                                                                                                                                           8
  [@B33]   5.2         National fracture registry confirmed                      39,938           Hip                                     Age, sex                                                                                                                                                                                                                                                                                                                                                                                                                        6
  [@B40]   6.7         National fracture registry confirmed                      255,936          Osteoporotic fracture                   Age, sex, calendar year, comorbidities, and exposure to the other classes of CVD-drugs                                                                                                                                                                                                                                                                                                                                          8
  [@B31]   9.7         Self-report and medical record or radiography confirmed   420              Vertebral                               BMI, race, physical activity, history of falls, smoking status, alcohol intake, supplemental calcium intake, quintiles of diet calcium intake, total vitamin D intake, vitamin A intake, total protein intake, self-reported diabetes or osteoporosis, history of beta-blocker use, bisphosphonate use, oral steroid use, or postmenopausal hormone use, and recent physical examination                                        9
  [@B10]   11          Health care registry confirmed                            128              Osteoporotic fracture                   Age, sex, comorbidities, and concurrent medication                                                                                                                                                                                                                                                                                                                                                                              7
  [@B26]   2           Health care registry confirmed                            167              Hip                                     Age, sex, socioeconomic factors, stroke severity, comorbidities, and concurrent medication                                                                                                                                                                                                                                                                                                                                      7
  [@B18]   1           Health care utilization data confirmed                    4,430            Osteoporotic fracture                   Age, sex, frailty index, socioeconomic factors, comorbidities, and concurrent medication                                                                                                                                                                                                                                                                                                                                        8
  [@B5]    6           Health care utilization data confirmed                    2,345            Osteoporotic fracture                   Age, sex, previous fracture, smoking, diabetes mellitus, cerebrovascular disease, chronic obstructive pulmonary disease, Parkinson's disease, alcoholism, use of antihypertensives other than thiazides (separately by each drug class), antiosteoporotic treatment, glucocorticosteroids, antidepressants/anxiolytics/sedatives, neuroleptics, antiepileptics, hormone replacement therapy, ethnicity, and educational level   8

BMD, bone mineral density; BMI, body mass index; CVD, cardiovascular diseases; DM, diabetes mellitus; GP, general practitioner.

Association Between Use of Thiazide Diuretics At Baseline and Fracture Incidence {#s3_3}
--------------------------------------------------------------------------------

Using a randomized-effect model, the pooled results of data from 17 cohorts indicated that use of thiazide diuretics at baseline did not significantly affect the risk of overall osteoporotic fracture incidence as compared with controls (RR: 0.96, 95% CI: 0.83 to 1.09, p = 0.51; [**Figure 2A**](#f2){ref-type="fig"}) with significant heterogeneity (p for Cochrane's Q test \< 0.001, I^2^ = 90%). Results of sensitivity analyses by omitting one study at a time did not significantly change the results (RR: 0.92∼0.98, p: 0.17∼0.77). Two of the studies included male participants exclusively ([@B28]; [@B7]), three included female participants exclusively ([@B8]; [@B14]; [@B31]), and two studies reported the outcome in male and female participants separately ([@B33]; [@B5]). By pooling the data from above studies, we found that use of thiazide diuretics at baseline was associated with significantly reduced incidence of overall osteoporotic fracture in male participants (RR: 0.78, 95% CI: 0.63 to 0.96, p = 0.02; I^2^ = 80%), but not in female participants (RR: 1.02, 95% CI: 0.79 to 1.30, p = 0.89; I^2^ = 89%; [**Figure 2B**](#f2){ref-type="fig"}). However, the results between the subgroups by sex were not significantly different (p = 0.11 for subgroup differences).

![Forest plots for the meta-analysis of the association between the use of thiazide diuretics and the incidence of fracture. **(A)** Forest plots for the overall participants; **(B)** forest plots for the subgroup analysis by sex.](fphar-10-01364-g002){#f2}

Results of Other Subgroup Analyses {#s3_4}
----------------------------------

The potential influences of other study characteristics on the association between thiazide diuretics and the risk of osteoporotic fracture were presented in [**Table 3**](#T3){ref-type="table"}. We found that use of thiazide diuretics at baseline did not significantly affect the risk of osteoporotic fracture regardless of study characteristics, such as study design, ethnicity, sample size, strategies for ascertainment of thiazides use, and extent of variables adjustment when presenting the results. Interestingly, we found that the sources of the participants may be an important determinant for the association between thiazide diuretics and subsequent risk of osteoporotic fracture ([**Figure 3**](#f3){ref-type="fig"}). In detail, use of thiazide diuretics was associated with significantly reduced risk of fracture in patients with new-onset stroke or spinal cord injury (RR: 0.70, 95% CI: 0.57 to 0.86, p \< 0.001; [**Figure 3**](#f3){ref-type="fig"}), but not in those of community-dwelling population or hypertensive patients (p for subgroup difference = 0.02; [**Figure 3**](#f3){ref-type="fig"}). Moreover, use of thiazide diuretics was associated with reduced risk of hip fracture (RR: 0.81, 95% CI: 0.69 to 0.94, p = 0.006), but not arm fracture. In addition, a significant association between use of thiazide diuretics and reduced fracture risk was observed in studies with follow-up duration ≤ 5 years (RR: 0.89, 95% CI: 0.80 to 1.00, p = 0.04), but not in those with follow-up duration \> 5 years. However, the influences of the site of fracture and the follow-up durations on the association between thiazide diuretics and incidence of osteoporotic fracture were not significant (p values for subgroup difference = 0.24 and 0.43, respectively).

###### 

Subgroup analysis for the association between thiazides use and the risk of fracture.

  Variables                            Dataset number   RR (95% CI)           P for subgroup effect   I^2^   P for subgroup difference
  ------------------------------------ ---------------- --------------------- ----------------------- ------ ---------------------------
  **Study design**                                                                                           
   PC                                  9                1.00 \[0.86, 1.16\]   0.99                    72%    
   RC                                  8                0.91 \[0.73, 1.14\]   0.42                    95%    0.51
  **Sex**                                                                                                    
   Male                                4                0.78 \[0.63, 0.96\]   0.02                    80%    
   Female                              5                1.02 \[0.79, 1.30\]   0.89                    89%    0.11
  **Ethnicity**                                                                                              
   Asians                              2                0.78 \[0.51, 1.17\]   0.23                    61%    
   Non-Asians                          15               0.98 \[0.85, 1.13\]   0.75                    91%    0.30
  **Number of participants**                                                                                 
   ≥10,000                             9                0.88 \[0.76, 1.01\]   0.07                    54%    
   \<10,000                            8                1.04 \[0.84, 1.28\]   0.72                    95%    0.19
  **Participants characteristics**                                                                           
   General population                  10               1.01 \[0.81, 1.27\]   0.91                    94%    
   Hypertensive                        5                0.93 \[0.85, 1.02\]   0.11                    40%    
   Stroke or spinal cord injury        2                0.70 \[0.57, 0.86\]   \< 0.001                0%     0.02
  **Follow-up**                                                                                              
   ≤5 years                            8                0.89 \[0.80, 1.00\]   0.04                    62%    
   \>5 years                           9                1.04 \[0.82, 1.32\]   0.74                    94%    0.24
  **Site of fracture**                                                                                       
   Hip fracture                        9                0.81 \[0.69, 0.94\]   0.006                   59%    
   Arm fracture                        3                0.92 \[0.70, 1.21\]   0.55                    59%    0.43
  **Ascertainment of thiazides use**                                                                         
   Self-report                         7                1.07 \[0.90, 1.27\]   0.44                    68%    
   Prescription records                10               0.89 \[0.74, 1.07\]   0.21                    93%    0.15
  **Numbers of variables adjusted**                                                                          
   ≤3                                  4                0.94 \[0.72, 1.23\]   0.67                    90%    
   \>3                                 13               0.96 \[0.83, 1.11\]   0.58                    87%    0.91

CI, confidence interval; PC, prospective cohort; RC, retrospective cohort; RR, risk ratio.

![Subgroup analyses for the association between the use of thiazide diuretics and the incidence of fracture by sources of the participants.](fphar-10-01364-g003){#f3}

Publication Bias {#s3_5}
----------------

The funnel plots regarding the association between use of thiazide diuretics at baseline and incidence of overall fracture were shown in [**Figure 4**](#f4){ref-type="fig"}. The funnel plots were symmetrical on visual inspection, suggesting low chance of significant publication bias. Results of Egger's regression test also suggested that no significant publication bias (p = 0.55).

![Funnel plots for the meta-analysis of the association between the use of thiazide diuretics and the incidence of fracture.](fphar-10-01364-g004){#f4}

Discussion {#s4}
==========

In this meta-analysis of cohort studies, we found that use of thiazide diuretics are not associated with significantly affected risk of osteoporotic fracture. The robustness of the study was further confirmed by the results of sensitivity analyses. Moreover, we found that the source and characteristics of the patients may be an important determinant for the association between use of thiazide diuretics and risk of osteoporotic fracture. Use of thiazide diuretics is associated with reduced risk of osteoporotic fracture in patients of acute clinical status including those with new-onset stroke or spinal cord injury, but not in those with generally good status such as community-dwelling population or hypertensive patients. These results challenged findings of previous studies that thiazide diuretics may be preventative against the incidence of osteoporotic fracture because of their efficacy for lowering urinary excretion of calcium.

The biological basis for the hypothesized association between use of thiazide diuretics and reduced risk of osteoporotic fracture are the potential benefits of thiazide diuretics on surrogate outcomes including urinary excretion of calcium and BMD ([@B25]; [@B24]). However, this is challenged by a recent meta-analysis which failed to show that thiazides improved BMD ([@B11]). Moreover, recent evidence suggests that strategies that favorably affect calcium homeostasis or BMD of the body may not necessarily translate to beneficial influence on clinical outcomes such as osteoporotic fracture. In a recently published meta-analysis, supplementation of calcium or/and vitamin D, previously established cornerstone therapy for osteoporosis, was shown to be not associated with a lower risk of fractures among community-dwelling people over 65 years ([@B47]). On the other hand, a previous RCT indicated that supplementation of calcium or/and vitamin D lowered the risk of osteoporotic fracture in individuals living in residential institutions ([@B9]). Interestingly, results of our subgroup analyses also suggested that the source and characteristics of the participants may be important determinant for the association between use of thiazide diuretics and the risk of osteoporotic fracture incidence. We did find a significant association between use of thiazide diuretics and the risk of osteoporotic fracture in patients with acute clinical status including new-onset stroke or spinal cord injury, but did not in community-dwelling participants or hypertensive patients. Taken together, these results suggested that benefits of certain treatment strategies on BMD may not translate to favorable influence on fracture risk in participants with relatively good condition such as community-dwelling population or hypertensive patients. In contrast, beneficial efficacy of certain treatment strategies on BMD may translate to lowering effectiveness on fracture risk in individuals of poor clinical status, such as those with poor mobility, infrequent sun exposure, and poor diet without sufficient intake of calcium and vitamin D, probably because these patients are more likely to have osteoporosis. Therefore, the potential association between thiazide diuretics and risk of osteoporotic fracture may be different among community-dwelling population, hypertensive patients, and patients with acute clinical status including new-onset stroke or spinal cord injury.

It should be also noted that despite of the potential benefits of thiazide diuretics on urinary excretion of calcium and BMD, use of thiazide diuretics may also be related to factors which may expose the participants to increased risk of osteoporotic fracture. For example, long-term use of thiazide diuretics may induce hyponatremia ([@B16]), which has recently been recognized as a potential risk factor for osteoporotic fracture ([@B42]; [@B4]). Moreover, prevalence of orthostatic hypotension was reported to be as high as 65% in elderly patients who took thiazide diuretics ([@B34]), and these patients were at higher risk for falls ([@B19]), a common cause of osteoporotic fracture. It is possible that hyponatremia, orthostatic hypotension, and falls resulted by the use of thiazide diuretics may offset their favorable influences on calcium homeostasis and BMD, which may finally lead to an insignificant influence of thiazide diuretics on the risk of osteoporotic fracture.

Although insignificant, results of our subgroup analyses also suggested that sex of the individuals, follow-up durations, and site of fractures may influence the association between use of thiazide diuretics and the risk of osteoporotic fracture. We found use of thiazide diuretics was associated with reduced risk of osteoporotic fracture in males rather than females, in short-term studies rather than long-term ones, and in those reporting outcomes of hip fractures rather than arm fractures. These results should be interpreted cautiously because the differences between the subgroups were not statistically significant. Future well-designed cohort studies with adequate sample size are needed to explore whether the above study characteristics (sex of the participants, follow-up durations, and sites of fractures) have significant influence on the association between use of thiazide diuretics and the risk of osteoporotic fracture.

Our study has limitations which should be considered when interpreting the results. Firstly, significant heterogeneity exists among the included studies. Although we explored the potential source of heterogeneity by performing the subgroup analyses, these results should be interpreted with caution because limited numbers of studies were available for each stratum of subgroups. Moreover, we did not have access to individual-patient based data, and the subgroup analyses were performed on the basis of study-level results. The potential influence of study characteristics on the outcome should be confirmed in future large-scale cohort studies. Secondly, as inherited in the meta-analysis of observational studies, we could not exclude the possibility of other factors that may confound the association between use of thiazide diuretics and the risk of osteoporotic fracture despite that we pooled the result with the most adequately adjusted data. Thirdly, we were unable to evaluate whether the association between use of thiazide diuretics and the risk of osteoporotic fracture differed according to the doses and durations of thiazides treatment. Finally, whether the association between use of thiazide diuretics and the risk of osteoporotic fracture differed among individual medication of thiazide diuretics should also be determined.

Conclusions {#s5}
===========

In conclusion, results of our meta-analysis indicated that use of thiazide diuretics is not associated with significantly affected risk of overall osteoporotic fracture. However, the association between use of thiazide diuretics and fracture risk may differ according to the general status of the participants.
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